ResMed Drops After Philips Return Fears; EPS Beat

ResMed sees midweek sell‑off despite solid quarterly results

ResMed (NYSE: RMD) experienced notable intraday volatility last week as investors reacted to a mix of analyst commentary and company results. The sequence — a sharp pullback followed by a partial rebound — was driven less by speculative headlines and more by concrete developments: an earnings beat, heightened trading volume, and opposing analyst actions tied to a possible Philips return to the U.S. CPAP space.

What moved the stock this week

Analyst actions and market sentiment

On February 10–12, ResMed shares declined across several sessions, then recovered modestly on February 13. The selling pressure coincided with a visible split among sell‑side analysts. Stifel lowered its price target to $260 and kept a “Hold” stance, pointing to the risk of Philips re‑entering the U.S. CPAP market and eroding ResMed’s near‑term share gains. In contrast, UBS reiterated a bullish view and set a significantly higher target of $345, arguing ResMed’s digital‑health momentum and margin profile justify upside.

Earnings snapshot: earnings beat and operational strength

ResMed’s Q2 FY2026 results delivered concrete positives. The company reported adjusted EPS of $2.81, beating consensus by roughly $0.13, and revenue of $1.42 billion — an approximate 11% year‑over‑year increase and ahead of street estimates. Management flagged gross margins in the low‑60s (around 62%–63%) and continued share‑repurchase activity, with buybacks expected to accelerate toward the $600 million range. Those figures underscore durable profitability and cash returns even as competitive questions linger.

Trading volume and short‑term price action

Volume picked up materially during the decline: intraday shares traded spiked above the 50‑day average, reflecting investor repositioning rather than thin‑market noise. The stock’s multi‑day retreat and subsequent bounce reflect a rapid repricing of risk — mostly tied to competition and valuation — against a still‑healthy operating performance.

Why Philips’ potential return matters

How Philips could affect ResMed

Philips historically was a major CPAP competitor; any re‑entry to the U.S. market could compress pricing and share for incumbents. Analysts quantifying that threat point to the potential of several hundred to a few thousand basis points of share movement over time, depending on product positioning, regulatory approvals, and reimbursement developments. For ResMed, the most immediate pressure would be in device sales and replacement cycles, though the company’s recurring revenue from masks, disposables, and software subscriptions provides some insulation.

Practical timeline and near‑term impact

Philips’ commercial impact is not instantaneous. Regulatory clearances, manufacturing scale‑up, and payer acceptance all take quarters. That means near‑term fundamental drivers — device demand, mask attach rates, and digital subscription growth — remain central to ResMed’s results. The analyst downgrade reflects a forward‑looking risk assessment rather than a sudden change in reported fundamentals.

Investor takeaways and positioning

Three practical points for investors:

• Fundamentals remain solid: ResMed beat EPS and revenue expectations and reports attractive margins plus active capital returns. These underpin long‑term durability.
• Risk is tangible, not speculative: Philips’ potential return is a concrete competitive variable — it just carries a timeline and execution risk that make it an assessable, not nebulous, threat.
• Volatility creates opportunities: Divergent price targets and active trading suggest short‑term mispricings. Long‑term investors focused on ResMed’s digital health moat and recurring revenue could view pullbacks as entry points, while those with shorter horizons should monitor share‑gain data and regulatory milestones tied to competitors.

Conclusion

Last week’s price moves in RMD were not random: they reflected a clear re‑evaluation of competitive risk against robust reported results. ResMed’s Q2 beat and strong margin profile support its strategic positioning in sleep and respiratory care, but near‑term returns to investors will depend on how effectively the company defends share should Philips intensify competition. The divergence among analysts — from Stifel’s more cautious $260 target to UBS’s $345 target — encapsulates that balance of measurable strength and identifiable risk.

For investors, the prudent response is disciplined monitoring: weigh ResMed’s recurring‑revenue growth and margin expansion against concrete signs of competitive disruption, and use volatility to recalibrate position sizing rather than chase headlines.